Common Histological Features Suggesting Enchondral Ossification Pathways in Calciphylaxis of Various Origins: A Study of Human Subcutaneous Tissue Biopsies
DOI:
https://doi.org/10.2340/actadv.v103.5755Keywords:
Bone Morphogenic Proteins, Calcific Uremic Arteriolopathy, Enchondral Ossification, Rare DiseasesAbstract
Calciphylaxis is a rare, yet underdiagnosed condition causing high mortality in patients with severe renal and cardiovascular disease. Since knowledge of the pathophysiology of calciphylaxis is limited, a differential analysis of histological alterations in patient subgroups with various comorbidities might expose different disease phenotypes and allow deeper insights into the pathophysiology of the condition. Histological markers of osteogenesis and calcification were investigated in a group of 18 patients with clinically and histologically verified calciphylaxis, using immunohistochemical staining. Analysis of staining intensity and distribution of marker proteins in histological structures was performed to evaluate distinct patterns between subgroups with different clinical comorbidities in comparison with a control group. In all cases, immunohistochemical staining for bone matrix proteins, bone-morphogenic proteins and matrix-Gla proteins co-localized with subcutaneous vascular and interstitial calcifications. Significant expression of bone-morphogenic protein-7 and active matrix-Gla protein was observed. Mortality was associated with renal comorbidities and increased expression of bone-morphogenic protein-7. However, no distinct histological patterns were found between subgroups with renal disease, warfarin intake or coexisting micro- and macro-angiopathies. The upregulation of osteogenic markers (including bone-morphogenic protein-7) plays a major role in the development of calciphylaxis. Clinical outcome correlates with kidney function and phosphate handling, suggesting different pathophysiological mechanisms. However, biopsy at late-stage disease shows a common histological phenotype, involving enchondral ossification.
Downloads
References
Colboc H, Moguelet P, Bazin D, Carvalho P, Dillies AS, Chaby G, et al. Localization, morphologic features, and chemical composition of calciphylaxis-related skin deposits in patients with calcific uremic arteriolopathy. JAMA Dermatol 2019; 155: 789-796.
https://doi.org/10.1001/jamadermatol.2019.0381 DOI: https://doi.org/10.1001/jamadermatol.2019.0381
Ghosh T, Winchester DS, Davis MDP, El-Azhary R, Comfere NI. Early clinical presentations and progression of calciphylaxis. Int J Dermatol 2017; 56: 856-861.
https://doi.org/10.1111/ijd.13622 DOI: https://doi.org/10.1111/ijd.13622
Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE Trial. Clin J Am Soc Nephrol 2015; 10: 800-807.
https://doi.org/10.2215/CJN.10221014 DOI: https://doi.org/10.2215/CJN.10221014
Gaisne R, Péré M, Menoyo V, Hourmant M, Larmet-Burgeot D. Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study. BMC Nephrol 2020; 21: 63.
https://doi.org/10.1186/s12882-020-01722-y DOI: https://doi.org/10.1186/s12882-020-01722-y
Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007; 56: 569-579.
https://doi.org/10.1016/j.jaad.2006.08.065 DOI: https://doi.org/10.1016/j.jaad.2006.08.065
Maroz N, Mohandes S, Field H, Kabakov Z, Simman R. Calciphylaxis in patients with preserved kidney function. J Am Coll Clin Wound Spec 2014; 6: 24-28.
https://doi.org/10.1016/j.jccw.2015.08.002 DOI: https://doi.org/10.1016/j.jccw.2015.08.002
Galloway PA, El-Damanawi R, Bardsley V, Pritchard NR, Fry AC, Ojha SK, et al. Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease. Nephron 2015; 129: 197-201.
https://doi.org/10.1159/000371449 DOI: https://doi.org/10.1159/000371449
Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y. A case-control study of calciphylaxis in japanese end-stage renal disease patients. Nephrol Dial Transplant 2012; 27: 1580-1584.
https://doi.org/10.1093/ndt/gfr658 DOI: https://doi.org/10.1093/ndt/gfr658
Pasch A, Farese S, Gräber S, Wald J, Richtering W, Floege J, et al. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012; 23: 1744-1752.
https://doi.org/10.1681/ASN.2012030240 DOI: https://doi.org/10.1681/ASN.2012030240
Jirak P, Stechemesser L, Moré E, Franzen M, Topf A, Mirna M, et al. Clinical implications of fetuin-A. Adv Clin Chem 2019; 89: 79-130.
https://doi.org/10.1016/bs.acc.2018.12.003 DOI: https://doi.org/10.1016/bs.acc.2018.12.003
Kutikhin AG, Feenstra L, Kostyunin AE, Yuzhalin AE, Hillebrands J-L, Krenning G. Calciprotein particles: balancing mineral homeostasis and vascular pathology. Arterioscler Thromb Vasc Biol 2021; 41: 1607-1624.
https://doi.org/10.1161/ATVBAHA.120.315697 DOI: https://doi.org/10.1161/ATVBAHA.120.315697
Bunting CH. The Formation of true bone with cellular (red) marrow in a sclerotic aorta. J Exp Med 1906; 8: 365-376.
https://doi.org/10.1084/jem.8.3.365 DOI: https://doi.org/10.1084/jem.8.3.365
Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154.
https://doi.org/10.1161/hh2401.101070 DOI: https://doi.org/10.1161/hh2401.101070
Engelse MA, Neele JM, Bronckers AL, Pannekoek H, de Vries CJ. Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor alpha-1 and the protective factor matrix gla protein in human atherogenesis. Cardiovasc Res 2001; 52: 281-289.
https://doi.org/10.1016/S0008-6363(01)00375-3 DOI: https://doi.org/10.1016/S0008-6363(01)00375-3
Griethe W, Schmitt R, Jurgensen JS, Bachmann S, Eckardt KU, Schindler R. Bone morphogenic protein-4 expression in vascular lesions of calciphylaxis. J Nephrol 2003; 16: 728-732.
Wu M, Rementer C, Giachelli CM. Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 2013; 93: 365-373.
https://doi.org/10.1007/s00223-013-9712-z DOI: https://doi.org/10.1007/s00223-013-9712-z
Nigwekar SU, Jiramongkolchai P, Wunderer F, Bloch E, Ichinose R, Nazarian RM, et al. Increased bone morphogenetic protein signaling in the cutaneous vasculature of patients with calciphylaxis. Am J Nephrol 2017; 46: 429-438.
https://doi.org/10.1159/000484418 DOI: https://doi.org/10.1159/000484418
Franzen M, Moré E, Cadamuro J, Koller J, Salmhofer W, Wohlmuth-Wieser I, et al. Mineral depositions of calcifying skin disorders are predominantly composed of carbonate apatite. Acta Derm Venereol 2017; 97: 1178-1181.
https://doi.org/10.2340/00015555-2739 DOI: https://doi.org/10.2340/00015555-2739
Paul S, Rabito CA, Vedak P, Nigwekar SU, Kroshinsky D. The role of bone scintigraphy in the diagnosis of calciphylaxis. JAMA Dermatol 2017; 153: 101-103.
https://doi.org/10.1001/jamadermatol.2015.4591 DOI: https://doi.org/10.1001/jamadermatol.2015.4591
Rrapi R, Chand S, Gabel C, Ko L, Moore KJ, Steele D, et al. Early diagnosis and intervention of calciphylaxis leading to rapid resolution. JAAD Case Rep 2021; 13: 65-70.
https://doi.org/10.1016/j.jdcr.2021.04.010 DOI: https://doi.org/10.1016/j.jdcr.2021.04.010
Jane B, Findenig B, Berr F, Dietze O, Hauser-Kronberger C, Salmhofer H. Calciphylaxis - calcified vsmcs show similarities with chondrocytes in the process of endochondral ossification. Wiener klinische Wochenschrift 2010; 122: A4-A4
Kramann R, Brandenburg VM, Schurgers LJ, Ketteler M, Westphal S, Leisten I, et al. Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant 2013; 28: 856-868.
https://doi.org/10.1093/ndt/gfs466 DOI: https://doi.org/10.1093/ndt/gfs466
Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105-114.
https://doi.org/10.1161/01.RES.00000175571.53833.6c DOI: https://doi.org/10.1161/01.RES.00000175571.53833.6c
Davies M, Lund R, Hruska K. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003; 14: 1559-1567.
https://doi.org/10.1097/01.ASN.0000068404.57780.DD DOI: https://doi.org/10.1097/01.ASN.0000068404.57780.DD
Liu L, Wang Y, Yan R, Liang L, Zhou X, Liu H, et al. BMP-7 inhibits renal fibrosis in diabetic nephropathy via miR-21 downregulation. Life Sci 2019; 238: 116957.
https://doi.org/10.1016/j.lfs.2019.116957 DOI: https://doi.org/10.1016/j.lfs.2019.116957
Park CH, Yoo TH. TGF-β inhibitors for therapeutic management of kidney fibrosis. Pharmaceuticals (Basel) 2022; 15: 1485.
https://doi.org/10.3390/ph15121485 DOI: https://doi.org/10.3390/ph15121485
Dorai H, Vukicevic S, Sampath TK. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 2000; 184: 37-45.
https://doi.org/10.1002/(SICI)1097-4652(200007)184:1<37::AID-JCP4>3.0.CO;2-M DOI: https://doi.org/10.1002/(SICI)1097-4652(200007)184:1<37::AID-JCP4>3.0.CO;2-M
Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610-1616.
https://doi.org/10.1161/hq1001.097102 DOI: https://doi.org/10.1161/hq1001.097102
Makarović S, Makarović Z, Steiner R, Mihaljević I, Milas-Ahić J. Osteoprotegerin and vascular calcification: clinical and prognostic relevance. Coll Antropol 2015; 39: 461-468.
Brandenburg V, Al-Fakhri N, Nemeth K, Goettsch C, Schurgers LJ, Vermeer C, et al. Calcification inhibitors in vascular calciphylaxis associated with normal renal Function. Thromb Haemost 2012; 108: 1241-1243.
https://doi.org/10.1160/TH12-07-0484 DOI: https://doi.org/10.1160/TH12-07-0484
Moe SM, Reslerova M, Ketteler M, O'Neill K, Duan D, Koczman J, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67: 2295-2304.
https://doi.org/10.1111/j.1523-1755.2005.00333.x DOI: https://doi.org/10.1111/j.1523-1755.2005.00333.x
Wei FF, Trenson S, Thijs L, Huang QF, Zhang ZY, Yang WY, et al. Desphospho-uncarboxylated matrix gla protein is a novel circulating biomarker predicting deterioration of renal function in the general population. Nephrol Dial Transplant 2018; 33: 1122-1128.
https://doi.org/10.1093/ndt/gfx258 DOI: https://doi.org/10.1093/ndt/gfx258
Rashdan NA, Sim AM, Cui L, Phadwal K, Roberts FL, Carter R, et al. Osteocalcin regulates arterial calcification via altered Wnt signaling and glucose metabolism. J Bone Miner Res 2020; 35: 357-367.
https://doi.org/10.1002/jbmr.3888 DOI: https://doi.org/10.1002/jbmr.3888
Dunaeva M, Waltenberger J. Hh signaling in regeneration of the ischemic heart. Cell Mol Life Sci 2017; 74: 3481-3490.
https://doi.org/10.1007/s00018-017-2534-9 DOI: https://doi.org/10.1007/s00018-017-2534-9
Dashti M, Peppelenbosch MP, Rezaee F. Hedgehog signalling as an antagonist of ageing and its associated diseases. Bioessays 2012; 34: 849-856.
https://doi.org/10.1002/bies.201200049 DOI: https://doi.org/10.1002/bies.201200049
Shuang F, Zhou Y, Hou SX, Zhu JL, Liu Y, Zhang CL, et al. Indian hedgehog signaling pathway members are associated with magnetic resonance imaging manifestations and pathological scores in lumbar facet joint osteoarthritis. Sci Rep 2015; 5: 10290.
https://doi.org/10.1038/srep10290 DOI: https://doi.org/10.1038/srep10290
Deng A, Zhang H, Hu M, Liu S, Gao Q, Wang Y, et al. Knockdown of Indian hedgehog protein induces an inhibition of cell growth and differentiation in osteoblast MC3T3‑E1 cells. Mol Med Rep 2017; 16: 7987-7992.
https://doi.org/10.3892/mmr.2017.7669 DOI: https://doi.org/10.3892/mmr.2017.7669
Additional Files
Published
How to Cite
License
Copyright (c) 2023 Simon Aberger, Barbara Findenig, Jane Beil, Nicole Aichinger, Josef Koller, Cees Vermeer, Leon Schurgers, Elke Theuwissen, Elena Moré, Michael Franzen, Cornelia Kronberger, Hermann Salmhofer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
